MOUNTAIN VIEW, Calif., Nov. 10 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the Company will present at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008, at 9:55 am (ET) in New York City.
A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals’ website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACT: Media, Julio Cantre, +1-415-946-1055, jcantre@wcpglobal.com, for
MAP Pharmaceuticals, Inc.
Web site: http://www.mappharma.com/
